To evaluate the potential prognostic impact of these biomarkers on specific subsets of breast cancer patients, overall survival curves were analyzed both in patients regardless of the molecular subtype of breast cancer and in those with specific subtypes, including basal-like, luminal A, luminal B, HER2, and normal-like carcinomas. This evidence concerns the gene ERBB2 and breast carcinoma.